





## WHO WE ARE

In Virginia, the major community partners engaged in health reform -- health care providers, health systems, health plans, pharmaceutical manufacturers and laboratory companies, employers, consumers, and government – came together to create a public-private partnership to accelerate the adoption of value-driven models of wellness and health care. This formal partnership is known as the Virginia Center for Health Innovation (VCHI).

These partners first came together in August 2010, when Governor McDonnell appointed 24 political, health system, civic and business leaders to the Virginia Health Reform Initiative Advisory Council. The Council was asked to develop recommendations about implementing health reform, and to seek innovative solutions that meet the needs of Virginia's citizens and its government. The creation of the Virginia Center for Health Innovation stemmed directly from one of these recommendations.

## WHAT WE DO

VCHI improves value in health care by focusing on four core services. These are:



Convening and Educating
Stakeholders interested in
accelerating the adoption
of value-driven models of
wellness and healthcare in
an effort to improve patient
outcomes and advance
Virginia's well-being and
economic competitiveness.



Overseeing and Facilitating
Demonstration Research to
test and evaluate models of
value-driven wellness and
health care.



Leveraging Data and
Analytical Resources
that educate and
equip health care
providers, public health
professionals, government
representatives, community
organizations, employers,
and consumers to make
more informed decisions.



Helping Prepare the Health
Care Workforce and the
Public for a high quality,
value-driven health care
marketplace which features
engaged and satisfied
clinicians and patients.

## THE VIRGINIA HEALTH VALUE DASHBOARD

In an effort to better understand how Virginia performs in delivering health value, and to determine how best to facilitate action for improvement where necessary, VCHI is launching the Virginia Health Value Dashboard. Funded with support from the Virginia General Assembly, the Dashboard includes three aims -- 1) reducing low value health care, 2) increasing high value health care, and 3) ensuring the Commonwealth has the necessary infrastructure to measure and reward value in health care. These three aims are captured by nine value indicators, which were approved by consensus at a joint meeting of the VCHI Board and Leadership Council.

As part of its Dashboard data collection and analytics effort, VCHI is partnering with the Virginia Association of Health Plans and Catalyst for Payment Reform (CPR) on CPR's Scorecard 2.0 initiative. Through this collaboration, Virginia will receive data on how much payment reform there is in the state and of what type. Scorecard 2.0 will also look at twelve metrics designed to better assess whether payment reform correlates with improved health care quality and affordability across the health care system. Collectively, this information will then feed into the larger Virginia Health Value Dashboard work.

**Colorectal Cancer Screening** 

27% • • • •

Legend	t'elw:	$\theta \rho_{MA}$	tsam <sub>U2</sub>		Cent	Easter,
REDUCING LOW VALUE CARE	5,5	\$	\ 0 0	So	ي ک	Fa
Utilization and Cost of Avoidable Emergency Room Visits						
Potentially Avoidable ED Visits - As a Percentage of Total ED Visits	13%	•	•	•	•	•
Potentially Avoidable ED Visits - Per 1,000 Member Months	3.2	•	•	•	•	•
Potentially Avoidable ED Visits - Per Member Per Year	0.04	•	•	•	•	•
Low Value Services as Captured by the MedInsight Health Waste Calculator						
Don't obtain baseline laboratory studies in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery – specifically complete blood count, basic or comprehensive metabolic panel, coagulation studies when blood loss (or fluid shifts) is/are expected to be minimal	83%	•	•	•	•	•
Don't obtain EKG, chest X-rays or pulmonary function test in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery	8%	•	•	•	•	•
Don't perform population based screening for 25-OH-Vitamin D deficiency	25%	•	•	•	•	•
Don't perform PSA-based screening for prostate cancer in all men regardless of age	75%	•	•	•	•	•
Don't do imaging for low back pain within the first six weeks, unless red flags are present	77%	•	•	•	•	•
Inappropriate Preventable Hospital Stays						
Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate (per 100,000 population)	2,160	•	•	•	•	•
INCREASING HIGH VALUE CARE	,					
Virginia Children and Adolescents who are Current with Appropriate Vaccination Schedules						
Childhood Immunization Status: DTaP	55%	•	•	•	•	•
Childhood Immunization Status: Influenza	47%	•	•	•	•	
Childhood Immunization Status: Hepatitis A	78%	•	•	•	•	
Childhood Immunization Status: Hepatitis B Childhood Immunization Status: HiB	24% 72%	•	•	•	•	
Childhood Immunization Status: IPV	66%	÷	•	•		
Childhood Immunization Status: NMR	81%	•	Ť	_	•	
Childhood Immunization Status: Pneumococcal Conjugate	56%	•	÷		•	•
Childhood Immunization Status: Prieumococcar Conjugate  Childhood Immunization Status: Rotavirus	55%	•	÷	÷		
Childhood Immunization Status: VZV	81%	_				
Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents	16%	•	•	•	•	•
Immunizations for Adolescents: HPV Vaccine	14%	•	•	•	•	•
Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine	56%	•	•	•	•	•
Immunizations for Adolescents: Tdap Vaccine	74%	•	•	•	•	•
Screening and Treatment of Virginia's Diabetic and Pre-Diabetic Population						
Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)	se	e CP	R Sco	reca	rd 2.0	
Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening		Cor	ning i	n 20	19	
Clinically Appropriate Cancer Screening Rates						
Breast Cancer Screening	57%	•	•	•	•	•
Cervical Cancer Screening	53%	•	•	•	•	•
	2=0/		-	-	-	

REDUCING LOW VALUE CARE	Numerator	Denominator	Rate
Utilization and Cost of Avoidable Emergency Room Visits			
Potentially Avoidable ED Visits - As a Percentage of Total ED Visits	204,112	1,525,336	13%
Potentially Avoidable ED Visits - Per 1,000 Member Months	204,112	63,466	3.2
Potentially Avoidable ED Visits - Per Member Per Year	204,112	5,288,861	0.04
Low Value Services as Captured by the MedInsight Health Waste Calculator	·		
Don't obtain baseline laboratory studies in patients without significant systemic disease			
(ASA I or II) undergoing low-risk surgery – specifically complete blood count, basic or			/
comprehensive metabolic panel, coagulation studies when blood loss (or fluid shifts)	417,580	504,827	83%
is/are expected to be minimal			
Don't obtain EKG, chest X-rays or pulmonary function test in patients without			
significant systemic disease (ASA I or II) undergoing low-risk surgery	32,518	426,836	8%
Don't perform population based screening for 25-OH-Vitamin D deficiency	123,950	487,412	25%
Don't perform PSA-based screening for prostate cancer in all men regardless of age	203,230	270,514	75%
Don't do imaging for low back pain within the first six weeks, unless red flags are			
present	31,670	41,304	77%
Inappropriate Preventable Hospital Stays			
Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate			
(per 100,000 population)	79,463	3,678,939	2,160
INCREASING HIGH VALUE CARE	Numerator	Denominator	Rate
Virginia Children and Adolescents who are Current with Appropriate Vaccination Schedules	Ivalificiator	Denominator	Nate
Childhood Immunization Status: DTaP	19,868	26.204	55%
Childhood Immunization Status: Influenza	•	36,394	
	17,054	36,394	47%
Childhood Immunization Status: Hepatitis A	28,389	36,394	78%
Childhood Immunization Status: Hepatitis B Childhood Immunization Status: HiB	8,668	36,394	24%
	26,137	36,394	72%
Childhood Immunization Status: IPV Childhood Immunization Status: MMR	23,940	36,394	66%
	29,627	36,394	81%
Childhood Immunization Status: Pneumococcal Conjugate Childhood Immunization Status: Rotavirus	20,454	36,394	56%
	20,071	36,394	55%
Childhood Immunization Status: VZV	29,513	36,394	81%
Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents	3,059	18,933	16%
Immunizations for Adolescents: HPV Vaccine	5,538	39,553	14%
Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal	22,083	39,553	56%
Polysaccharide Vaccine	20.405	20.552	740/
Immunizations for Adolescents: Tdap Vaccine	29,185	39,553	74%
Screening and Treatment of Virginia's Diabetic and Pre-Diabetic Population			
Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening	See CF	R Scorecard 2.0	)
During the Measurement Year (HEDIS=1 year)			
Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening	Coi	ming in 2019	
Clinically Appropriate Cancer Screening Rates			
Breast Cancer Screening	126,565	223,390	57%
Cervical Cancer Screening	257,202	483,930	53%
Colorectal Cancer Screening	327,238	1,191,337	27%
IMPROVING THE INFRASTRUCTURE FOR VALUE BASED CARE	Numerator	Denominator	Rate
Value-Oriented Payments that Place Doctors and Hospitals at Financial Risk for Performance		R Scorecard 2.0	_
Percentage of Commercial In-Network Payments that are Value-Oriented		R Scorecard 2.0	
Percent of Virginia Total Covered Lives with Claims Included in the Virginia All Payer			
Claims Database	4,310,742	7,361,200	59%
Percent of Virginia Commercially Insured Lives with Claims included in the Virginia All			
Payer Claims Database	2,005,487	4,891,600	41%
. aja: ciamo autobac			

Utilization and Cost of Avoidable Emergency Room Visits           Potentially Avoidable ED Visits - As a Percentage of Total ED Visits         28,547         9,860         2.9           Potentially Avoidable ED Visits - Per L000 Member Months         28,547         9,860         2.9           Potentially Avoidable ED Visits - Per Member Per Year         28,547         821,634         0.03           Low Value Services os Captured by the Medinsight Health Waste Colculor         68,387         82,054         83%           Lon't Optian Baseline laboratory studies in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery — specifically complete blood count, basic or comprehensive metabolic panel, coagulation studies when blood loss (or fluid shirls) is/are expected to be minimal         5,138         67,687         8%           Don't bperform persent Secure in got 25-OH-Vitamin D deficiency         18,801         77,672         24%           Don't perform population based screening for 25-OH-Vitamin D deficiency         18,801         77,672         24%           Don't do imaging for low back pain within the first six weeks, unless red flags are persent         4,644         6,251         74%           Inappropriate Preventable Hospital Stays         14,768         577,299         2,558           Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate (per 100,000 population)         2,981         5,541         <	REDUCING LOW VALUE CARE	Numerator	Denominator	Rate
Potentially Avoidable ED Visits - Per 1,000 Member Months Potentially Avoidable ED Visits - Per Member Per Year  28,547 821,634 0.03  Low Value Services as Captured by the Medinsight Health Waste Calculator  Don't obtain baseline laboratory studies in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery - specifically complete blood count, basic or comprehensive metabolic panel, coagulation studies when blood loss (or fluid shifts) is/are expected to be minimal  Don't obtain EKG, chest X-rays or pulmonary function test in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery  Don't perform population based screening for 25-OH-Vitamin D deficiency  Don't perform PSA-based screening for prostate cancer in all men regardless of age  Don't do imaging for low back pain within the first six weeks, unless red flags are present  Inappropriate Preventable Hospital Stays  Inappropri	Utilization and Cost of Avoidable Emergency Room Visits			
Potentially Avoidable ED Visits - Per Member Per Year  Low Value Services as Captured by the Medinsight Health Waste Calculator  Don't obtain baseline laboratory studies in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery - specifically complete blood count, basic or comprehensive metabolic panel, coagulation studies when blood loss (or fluid shifts) is/are expected to be minimal  Don't obtain EKG, chest X-rays or pulmonary function test in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery  Don't perform population based screening for 25-OH-Vitamin D deficiency  Don't perform PSA-based screening for prostate cancer in all men regardless of age  31,415  33,065  73%  Don't do imaging for low back pain within the first six weeks, unless red flags are present  Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate (pp. 40,000 population)  INCREASING HIGH VALUE CARE  Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate (pp. 40,000 population)  INCREASING HIGH VALUE CARE  Prevention Quality Indicator \$190: Prevention Quality Overall Composite National Acadescents who are Current with Appropriate Vaccination Scheduse  Virginia Children and Adolescents who are Current with Appropriate Vaccination Scheduse  Virginia Children and Adolescents who are Current with Appropriate Vaccination Scheduse  Virginia Children and Adolescents who are Current with Appropriate Vaccination Scheduse  Virginia Children and Adolescents who are Current with Appropriate Vaccination Scheduse  Virginia Children and Adolescents who are Current with Appropriate Vaccination Scheduse  Virginia Children and Adolescents who are Current with Appropriate Vaccination Scheduse  Virginia Children and Adolescents who are Current with Appropriate Vaccination Scheduse  Virginia Children and Adolescents with Appropriate Vaccination Scheduse  Virginia Children and Adolescents with Appropriate Vaccination Scheduse  Virginia Children and Adole	Potentially Avoidable ED Visits - As a Percentage of Total ED Visits	28,547	243,440	12%
Don't obtain baseline laboratory studies in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery - specifically complete blood count, basic or comprehensive metabolic panel, coagulation studies when blood loss (or fluid shifts) is/are expected to be minimal Don't obtain take (KG, chest X-rays or pulmonary function test in patients without significant systemic disease (ASA I or III) undergoing low-risk surgery  Don't perform population based screening for 25-OH-Vitamin D deficiency 18,801 74,672 24% only the perform population based screening for 25-OH-Vitamin D deficiency 31,415 34,065 73% 24% 24,644 34,065 73% 24% 24,644 34,065 73% 24% 24,644 34,065 73% 24,644 34,065 73% 24,644 34,065 74% 24,065 74% 24,065 7	Potentially Avoidable ED Visits - Per 1,000 Member Months	28,547	9,860	2.9
Don't obtain baseline laboratory studies in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery – specifically complete blood count, basic or comprehensive metabolic panel, coagulation studies when blood loss (or fluid shifts) is/are expected to be minimal  Don't obtain EKG, chest X-rays or pulmonary function test in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery Don't obtain EKG, chest X-rays or pulmonary function test in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery Don't perform population based screening for 25-OH-Vitamin D deficiency 18,801 77,672 24% Don't perform pSA-based screening for prostate cancer in all men regardless of age 31,415 43,065 73% Don't do imaging for low back pain within the first six weeks, unless red flags are present  Inappropriate Preventable Hospital Stays  Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate (per 100,000 population)  INCREASING HIGH VALUE CARE  Virginia Children and Adolescents who are Current with Appropriate Vaccination Schedules  INCREASING HIGH VALUE CARE  Virginia Children and Adolescents who are Current with Appropriate Vaccination Schedules  Childhood Immunization Status: Hepatitis A  Childhood Immunization Status: Hepatitis A  Childhood Immunization Status: Hepatitis A  Childhood Immunization Status: Hepatitis B  Childhood Immunization Status: Hepatitis A  Childhood Immunization Status: WMR  Childhood Immunization Status: Preumococal Conjugate  Childhood Immunization Status: Rotavirus  Childhood Immuniza	Potentially Avoidable ED Visits - Per Member Per Year	28,547	821,634	0.03
(ASA 1or II) undergoing low-risk surgery — specifically complete blood count, basic or comprehensive metabolic panel, coagulation studies when blood loss (or fluid shifts) is/fare expected to be minimal  Don't obtain EKG, chest X-rays or pulmonary function test in patients without significant systemic disease (ASA 1 or II) undergoing low-risk surgery  Don't perform population based screening for 25-OH-Vitamin D deficiency  Don't perform PSA-based screening for prostate cancer in all men regardless of age  14,644  Don't do imaging for low back pain within the first six weeks, unless red flags are present  14,768  Don't do imaging for low back pain within the first six weeks, unless red flags are present  14,768  14,768  577,299  2,558  INCREASING HIGH VALUE CARE  Wireinia Children and Adolescents who are Current with Appropriate Vaccination Schelus  Childhood Immunization Status: DTaP  Childhood Immunization Status: Influenza  Childhood Immunization Status: Hepatitis A  Childhood Immunization Status: Hepatitis B  Childhood Immunization Status: Hepatitis B  Childhood Immunization Status: Hepatitis B  Childhood Immunization Status: Hildenza  Childhood Immunization Statu	Low Value Services as Captured by the MedInsight Health Waste Calculator			
significant systemic disease (ASA I or II) undergoing low-risk surgery  Don't perform population based screening for 25-OH-Vittamin D deficiency  Don't perform PSA-based screening for prostate cancer in all men regardless of age Don't do imaging for low back pain within the first six weeks, unless red flags are present  Inappropriate Preventable Hospital Stays  Inappropriate Preventable Hospital Stays  Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate (per 100,000 population)  INCREASING HIGH VALUE CARE  Numerator  Virginia Children and Adolescents who are Current with Appropriate Vaccination Schedues  Childhood Immunization Status: Influenza Childhood Immunization Status: Hepatitis A Childhood Immunization Status: Hepatitis B Childhood Immunization Status: Hepatitis B Childhood Immunization Status: Hille Childhood Immunization Status: WMR Childhood Immunization Status: Rotavirus  Childhood Immunizati	(ASA I or II) undergoing low-risk surgery – specifically complete blood count, basic or comprehensive metabolic panel, coagulation studies when blood loss (or fluid shifts)		82,054	83%
Don't perform PSA-based screening for prostate cancer in all men regardless of age       31,415       43,065       73%         Don't do imaging for low back pain within the first six weeks, unless red flags are present       4,644       6,251       74%         Inappropriate Preventable Hospital Stays       Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate (per 100,000 population)       14,768       577,299       2,558         INCREASING HIGH VALUE CARE       Numerator       Denominator       Rate         Virginia Children and Adolescents who are Current with Appropriate Vaccination Schaules       2,981       5,541       54%         Childhood Immunization Status: Influenza       2,981       5,541       54%         Childhood Immunization Status: Hepatitis A       4,012       5,541       25%         Childhood Immunization Status: Hepatitis B       1,522       5,541       63%         Childhood Immunization Status: IRB       3,761       5,541       63%         Childhood Immunization Status: WIP       3,492       5,541       63%         Childhood Immunization Status: Preumococcal Conjugate       3,061       5,541       55%         Childhood Immunization Status: Preumococcal Conjugate       3,061       5,541       55%         Childhood Immunization Status: VZV       4,244       <		5,138	67,687	8%
Don't do imaging for low back pain within the first six weeks, unless red flags are present  Inappropriate Preventable Hospital Stays Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate (per 100,000 population)  Increasing HIGH VALUE CARE  Numerator	Don't perform population based screening for 25-OH-Vitamin D deficiency	18,801	77,672	24%
Inappropriate Preventable Hospital Stays         Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate (per 100,000 population)       14,768       577,299       2,558         INCREASING HIGH VALUE CARE       Numerator       Denominator       Retermination Status: Perpention Quality Overall Composite Rate (per 100,000 population)       2,981       5,541       54%         Childhood Immunization Status: DTAP       2,981       5,541       45%         Childhood Immunization Status: Hepatitis A       4,012       5,541       27%         Childhood Immunization Status: Hepatitis B       1,522       5,541       27%         Childhood Immunization Status: Hilb       3,761       5,541       68%         Childhood Immunization Status: HW       3,492       5,541       68%         Childhood Immunization Status: MMR       4,314       5,541       78%         Childhood Immunization Status: Repatitis B       3,061       5,541       78%         Childhood Immunization Status: MMR       4,314       5,541       78%         Childhood Immunization Status: Repatitis B       4,244       5,541       75%         Childhood Immunization Status: Repatitis Rotavirus       3,061       5,541       55%         Childhood Immunization Status: Repatitis Rotavirus       3,051       5,541	Don't perform PSA-based screening for prostate cancer in all men regardless of age	31,415	43,065	73%
Inappropriate Preventable Hospital Stays Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate (per 100,000 population)  INCREASING HIGH VALUE CARE  Virginia Children and Adolescents who are Current with Appropriate Vaccination Schedules Childhood Immunization Status: DTaP  Childhood Immunization Status: Influenza  Childhood Immunization Status: Hepatitis A  Childhood Immunization Status: Hepatitis B  Childhood Immunization Status: Hepatitis B  Childhood Immunization Status: HBB  Childhood Immunization Status: Preumococcal Conjugate  Childhood Immunization Status: Preumococcal Conjugate  Childhood Immunization Status: Pneumococcal Conjugate  Childhood Immunization Status: Pneumococcal Conjugate  A 3,051  Childhood Immunization Status: Pneumococcal Conjugate  Childhood Immunization Status: Rotavirus  Childhood Immunization Status: Rotavirus  Childhood Immunization Status: Pneumococcal Conjugate  Childhood Immunization Status: Pneumococcal Conjugate  Childhood Immunization Status: Pneumococcal Conjugate or Meningococcal  Childhood Immunization Status:	Don't do imaging for low back pain within the first six weeks, unless red flags are	4.644	C 251	740/
Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate (per 100,000 population)14,768577,2992,588INCREASING HIGH VALUE CARENumeratorDenominatorRateVirginia Children and Adolescents who are Current with Appropriate Vaccination Schedules5,54154%Childhood Immunization Status: Drīpu2,9815,54154%Childhood Immunization Status: Hepatitis A2,5085,54172%Childhood Immunization Status: Hepatitis B1,5225,54127%Childhood Immunization Status: HilB3,7615,54168%Childhood Immunization Status: HWR3,7615,54168%Childhood Immunization Status: PV3,4925,54178%Childhood Immunization Status: PNeumococcal Conjugate3,0615,54178%Childhood Immunization Status: Rotavirus3,0615,54155%Childhood Immunization Status: Rotavirus3,0615,54155%Childhood Immunization Status: Rotavirus3,0615,54155%Childhood Immunization Status: Rotavirus4,2445,54177%Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents4,2445,54115%Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal2,9465,93813%Immunizations for Adolescents: Tdap Vaccine4,2805,93873%Polysaccharide Vaccine4,2805,93873%Immunizations for Adolescents: Tdap Vaccine4,2805,93873%Erccentage of Patients 18-75 Years	present	4,644	0,251	74%
Increasing High Value Care   Numerator   Denominator   Rate   Virginia Children and Adolescents who are Current with Appropriate Vaccination Schedules	Inappropriate Preventable Hospital Stays			
Virginia Children and Adolescents who are Current with Appropriate Vaccination SchedulesChildhood Immunization Status: DTaP2,9815,54154%Childhood Immunization Status: Influenza2,5085,54145%Childhood Immunization Status: Hepatitis A4,0125,54172%Childhood Immunization Status: Hepatitis B1,5225,54127%Childhood Immunization Status: HIB3,7615,54168%Childhood Immunization Status: IPV3,4925,54163%Childhood Immunization Status: MMR4,3145,54178%Childhood Immunization Status: Pneumococcal Conjugate3,0615,54155%Childhood Immunization Status: Rotavirus3,0515,54155%Childhood Immunization Status: Rotavirus3,0515,54177%Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents4212,87115%Immunizations for Adolescents: HPV Vaccine7485,93813%Polysaccharide Vaccine4,2805,93870%Immunizations for Adolescents: Tdap Vaccine4,2805,93870%Screening and Treatment of Virginia's Diabetic and Pre-Diabetic PopulationPercentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)Coming in 2019		14,768	577,299	2,558
Childhood Immunization Status: DTAP2,9815,54154%Childhood Immunization Status: Influenza2,5085,54145%Childhood Immunization Status: Hepatitis A4,0125,54172%Childhood Immunization Status: Hepatitis B1,5225,54127%Childhood Immunization Status: HIB3,7615,54168%Childhood Immunization Status: IPV3,4925,54163%Childhood Immunization Status: MMR4,3145,54178%Childhood Immunization Status: Pneumococcal Conjugate3,0615,54155%Childhood Immunization Status: Rotavirus3,0515,54155%Childhood Immunization Status: VZV4,2445,54177%Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents4212,87115%Immunizations for Adolescents: HPV Vaccine7485,93813%Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine2,9465,93850%Immunizations for Adolescents: Tdap Vaccine4,2805,93872%Screening and Treatment of Virginia's Diabetic and Pre-Diabetic PopulationPercentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)ScottlerComing in 2019	INCREASING HIGH VALUE CARE	Numerator	Denominator	Rate
Childhood Immunization Status: Influenza2,5085,54145%Childhood Immunization Status: Hepatitis A4,0125,54172%Childhood Immunization Status: Hepatitis B1,5225,54127%Childhood Immunization Status: HiB3,7615,54168%Childhood Immunization Status: IPV3,4925,54163%Childhood Immunization Status: MMR4,3145,54178%Childhood Immunization Status: Pneumococcal Conjugate3,0615,54155%Childhood Immunization Status: Rotavirus3,0515,54155%Childhood Immunization Status: VZV4,2445,54177%Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents4212,87115%Immunizations for Adolescents: HPV Vaccine7485,93813%Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine2,9465,93870%Polysaccharide Vaccine4,2805,93870%Screening and Treatment of Virginia's Diabetic and Pre-Diabetic PopulationPercentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)Scombig in 2019Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy ScreeningCombig in 2019	Virginia Children and Adolescents who are Current with Appropriate Vaccination Schedules			
Childhood Immunization Status: Hepatitis A4,0125,54172%Childhood Immunization Status: Hepatitis B1,5225,54127%Childhood Immunization Status: HiB3,7615,54168%Childhood Immunization Status: IPV3,4925,54163%Childhood Immunization Status: MMR4,3145,54178%Childhood Immunization Status: Pneumococcal Conjugate3,0615,54155%Childhood Immunization Status: Rotavirus3,0515,54155%Childhood Immunization Status: VZV4,2445,54177%Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents4212,87115%Immunizations for Adolescents: HPV Vaccine7485,93813%Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine2,9465,93850%Screening and Treatment of Virginia's Diabetic and Pre-Diabetic PopulationPercentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening Ouring the Measurement Year (HEDIS=1 year)See CPR Scorecard 2.0Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy ScreeningComing in 2019	Childhood Immunization Status: DTaP	2,981	5,541	54%
Childhood Immunization Status: Hepatitis B1,5225,54127%Childhood Immunization Status: HiB3,7615,54168%Childhood Immunization Status: IPV3,4925,54163%Childhood Immunization Status: MMR4,3145,54178%Childhood Immunization Status: Pneumococcal Conjugate3,0615,54155%Childhood Immunization Status: Rotavirus3,0515,54155%Childhood Immunization Status: VZV4,2445,54177%Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents4212,87115%Immunizations for Adolescents: HPV Vaccine7485,93813%Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine2,9465,93850%Immunizations for Adolescents: Tdap Vaccine4,2805,93872%Screening and Treatment of Virginia's Diabetic and Pre-Diabetic PopulationPercentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)Coming in 2019Coming in 2019	Childhood Immunization Status: Influenza	2,508	5,541	45%
Childhood Immunization Status: HiB3,7615,54168%Childhood Immunization Status: IPV3,4925,54163%Childhood Immunization Status: MMR4,3145,54178%Childhood Immunization Status: Pneumococcal Conjugate3,0615,54155%Childhood Immunization Status: Rotavirus3,0515,54155%Childhood Immunization Status: VZV4,2445,54177%Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents4212,87115%Immunizations for Adolescents: HPV Vaccine7485,93813%Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine2,9465,93850%Immunizations for Adolescents: Tdap Vaccine4,2805,93872%Screening and Treatment of Virginia's Diabetic and Pre-Diabetic PopulationPercentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)Coming in 2019	Childhood Immunization Status: Hepatitis A	4,012	5,541	72%
Childhood Immunization Status: IPV Childhood Immunization Status: MMR Childhood Immunization Status: MMR Childhood Immunization Status: Pneumococcal Conjugate Childhood Immunization Status: Pneumococcal Conjugate 3,061 5,541 55% Childhood Immunization Status: Rotavirus 3,051 5,541 55% Childhood Immunization Status: VZV 4,244 5,541 77% Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents 421 2,871 15% Immunizations for Adolescents: HPV Vaccine 748 5,938 13% Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine Immunizations for Adolescents: Tdap Vaccine Immunizations for Adolescents: Tdap Vaccine 4,280 5,938 72%  Screening and Treatment of Virginia's Diabetic and Pre-Diabetic Population Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)  Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening  Coming in 2019	Childhood Immunization Status: Hepatitis B	1,522	5,541	27%
Childhood Immunization Status: MMR  Childhood Immunization Status: Pneumococcal Conjugate  3,061 5,541 55% Childhood Immunization Status: Rotavirus 3,051 5,541 55% Childhood Immunization Status: Rotavirus 3,051 5,541 55% Childhood Immunization Status: VZV 4,244 5,541 77% Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents 421 2,871 15% Immunizations for Adolescents: HPV Vaccine 748 5,938 13% Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine Immunizations for Adolescents: Tdap Vaccine 4,280 5,938 72%  Screening and Treatment of Virginia's Diabetic and Pre-Diabetic Population Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)  Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening	Childhood Immunization Status: HiB	3,761	5,541	68%
Childhood Immunization Status: Pneumococcal Conjugate  3,061 5,541 55% Childhood Immunization Status: Rotavirus 3,051 5,541 55% Childhood Immunization Status: VZV 4,244 5,541 77% Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents 421 2,871 15% Immunizations for Adolescents: HPV Vaccine 748 5,938 13% Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine 12,946 5,938 50% Screening and Treatment of Virginia's Diabetic and Pre-Diabetic Population Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)  Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening	Childhood Immunization Status: IPV	3,492	5,541	63%
Childhood Immunization Status: Rotavirus  Childhood Immunization Status: VZV  4,244 5,541 77%  Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents 421 2,871 15%  Immunizations for Adolescents: HPV Vaccine 748 5,938 13%  Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine 2,946 5,938 50%  Screening and Treatment of Virginia's Diabetic and Pre-Diabetic Population  Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)  Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening  Coming in 2019	Childhood Immunization Status: MMR	4,314	5,541	78%
Childhood Immunization Status: VZV Human Papillomavirus (HPV) Vaccine for Female Adolescents Human Papillomavirus (HPV) Vaccine for Female Adolescents Immunizations for Adolescents: HPV Vaccine Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine Immunizations for Adolescents: Tdap Vaccine Immunizations for Adolescents: Tdap Vaccine  Screening and Treatment of Virginia's Diabetic and Pre-Diabetic Population Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)  Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening  Coming in 2019	Childhood Immunization Status: Pneumococcal Conjugate	3,061	5,541	55%
Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents 421 2,871 15% Immunizations for Adolescents: HPV Vaccine 748 5,938 13% Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine 2,946 5,938 50% Immunizations for Adolescents: Tdap Vaccine 4,280 5,938 72% Screening and Treatment of Virginia's Diabetic and Pre-Diabetic Population  Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)  Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening	Childhood Immunization Status: Rotavirus	3,051	5,541	55%
Immunizations for Adolescents: HPV Vaccine7485,93813%Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine2,9465,93850%Immunizations for Adolescents: Tdap Vaccine4,2805,93872%Screening and Treatment of Virginia's Diabetic and Pre-Diabetic PopulationPercentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)see CPR Scorecard 2.0Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy ScreeningComing in 2019	Childhood Immunization Status: VZV	4,244	5,541	77%
Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal 2,946 5,938 50% Polysaccharide Vaccine 2,946 5,938 72% Immunizations for Adolescents: Tdap Vaccine 4,280 5,938 72% Screening and Treatment of Virginia's Diabetic and Pre-Diabetic Population  Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)  Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening	Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents	421	2,871	15%
Polysaccharide Vaccine  Immunizations for Adolescents: Tdap Vaccine  Screening and Treatment of Virginia's Diabetic and Pre-Diabetic Population  Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)  Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening  Coming in 2019	Immunizations for Adolescents: HPV Vaccine	748	5,938	13%
Immunizations for Adolescents: Tdap Vaccine  Screening and Treatment of Virginia's Diabetic and Pre-Diabetic Population  Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)  Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening  Coming in 2019		2.946	5.938	50%
Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)  Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening  Coming in 2019	·			
Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)  Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening  Coming in 2019	·	4,280	5,938	72%
During the Measurement Year (HEDIS=1 year)  Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening  Coming in 2019				
Screening Coming in 2019		see CF	PR Scorecard 2.0	)
Clinically Appropriate Cancer Screening Rates		Cor	ming in 2019	
	Clinically Appropriate Cancer Screening Rates			
Breast Cancer Screening 16,360 31,144 53%	Breast Cancer Screening	16,360	31,144	53%
Cervical Cancer Screening 34,656 68,246 51%	Cervical Cancer Screening	34,656	68,246	51%
Colorectal Cancer Screening 49,309 189,955 26%	Colorectal Cancer Screening	49,309	189,955	26%

ilization and Cost of Avoidable Emergency Room Visits	Numerator	Denominator	Rate
manus and out of reviewer Emergency Routh Visits			
tentially Avoidable ED Visits - As a Percentage of Total ED Visits	28,207	254,248	11%
tentially Avoidable ED Visits - Per 1,000 Member Months	28,207	16,748	1.7
tentially Avoidable ED Visits - Per Member Per Year	28,207	1,395,646	0.02
w Value Services as Captured by the MedInsight Health Waste Calculator			
on't obtain baseline laboratory studies in patients without significant systemic disease SA I or II) undergoing low-risk surgery – specifically complete blood count, basic or imprehensive metabolic panel, coagulation studies when blood loss (or fluid shifts) are expected to be minimal	94,030	109,794	86%
on't obtain EKG, chest X-rays or pulmonary function test in patients without gnificant systemic disease (ASA I or II) undergoing low-risk surgery	13,717	82,435	17%
on't perform population based screening for 25-OH-Vitamin D deficiency	60,242	146,953	41%
on't perform PSA-based screening for prostate cancer in all men regardless of age	53,041	65,836	81%
on't do imaging for low back pain within the first six weeks, unless red flags are esent	6,091	8,349	73%
appropriate Preventable Hospital Stays			
evention Quality Indicator #90: Prevention Quality Overall Composite Rate er 100,000 population)	11,277	958,921	1,176
CREASING HIGH VALUE CARE	Numerator	Denominator	Rate
rginia Children and Adolescents who are Current with Appropriate Vaccination Schedules			
ildhood Immunization Status: DTaP	5,778	10,282	56%
ildhood Immunization Status: Influenza	5,694	10,282	55%
ildhood Immunization Status: Hepatitis A	8,543	10,282	83%
ildhood Immunization Status: Hepatitis B	2,601	10,282	25%
ildhood Immunization Status: HiB	7,325	10,282	71%
ildhood Immunization Status: IPV	6,855	10,282	67%
ildhood Immunization Status: MMR	8,492	10,282	83%
ildhood Immunization Status: Pneumococcal Conjugate	5,834	10,282	57%
ildhood Immunization Status: Rotavirus	5,903	10,282	57%
ildhood Immunization Status: VZV	8,462	10,282	82%
ıman Papillomavirus Virus (HPV) Vaccine for Female Adolescents	1,012	4,974	20%
munizations for Adolescents: HPV Vaccine	1,897	10,523	18%
munizations for Adolescents: Meningococcal Conjugate or Meningococcal lysaccharide Vaccine	6,592	10,523	63%
munizations for Adolescents: Tdap Vaccine	7,702	10,523	73%
reening and Treatment of Virginia's Diabetic and Pre-Diabetic Population			
rcentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening	see CP	R Scorecard 2.0	
rcentage of Patients 18-75 Years of Age with Diabetes who had AbATC Screening rring the Measurement Year (HEDIS=1 year)			
	Сог	ming in 2019	
rring the Measurement Year (HEDIS=1 year) rcentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy	Cor	ming in 2019	
rring the Measurement Year (HEDIS=1 year) rcentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy reening	Cor 39,296	ming in 2019 58,350	67%
rring the Measurement Year (HEDIS=1 year) rcentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy reening inically Appropriate Cancer Screening Rates		-	67% 70%

REDUCING LOW VALUE CARE	Numerator	Denominator	Rate
Utilization and Cost of Avoidable Emergency Room Visits			
Potentially Avoidable ED Visits - As a Percentage of Total ED Visits	46,909	334,774	14%
Potentially Avoidable ED Visits - Per 1,000 Member Months	46,909	11,908	3.9
Potentially Avoidable ED Visits - Per Member Per Year	46,909	992,338	0.05
Low Value Services as Captured by the MedInsight Health Waste Calculator			
Don't obtain baseline laboratory studies in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery – specifically complete blood count, basic or comprehensive metabolic panel, coagulation studies when blood loss (or fluid shifts) is/are expected to be minimal	82,151	99,957	82%
Don't obtain EKG, chest X-rays or pulmonary function test in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery	4,472	99,064	5%
Don't perform population based screening for 25-OH-Vitamin D deficiency	13,147	80,567	16%
Don't perform PSA-based screening for prostate cancer in all men regardless of age	35,440	46,620	76%
Don't do imaging for low back pain within the first six weeks, unless red flags are present	6,020	7,993	75%
Inappropriate Preventable Hospital Stays			
Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate (per 100,000 population)	21,428	732,566	2,925
INCREASING HIGH VALUE CARE	Numerator	Denominator	Rate
Virginia Children and Adolescents who are Current with Appropriate Vaccination Schedules			
Childhood Immunization Status: DTaP	3,347	6,235	54%
Childhood Immunization Status: Influenza	2,513	6,235	40%
Childhood Immunization Status: Hepatitis A	4,830	6,235	77%
Childhood Immunization Status: Hepatitis B	2,520	6,235	40%
Childhood Immunization Status: HiB	4,430	6,235	71%
Childhood Immunization Status: IPV	4,116	6,235	66%
Childhood Immunization Status: MMR	5,120	6,235	82%
Childhood Immunization Status: Pneumococcal Conjugate	3,533	6,235	57%
Childhood Immunization Status: Rotavirus	3,636	6,235	58%
Childhood Immunization Status: VZV	5,136	6,235	82%
Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents	540	3,337	16%
Immunizations for Adolescents: HPV Vaccine	932	7,000	13%
Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine	3,537	7,000	51%
Immunizations for Adolescents: Tdap Vaccine	5,207	7,000	74%
Screening and Treatment of Virginia's Diabetic and Pre-Diabetic Population			
Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)	see CF	PR Scorecard 2.0	
Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening	Cor	ming in 2019	
Clinically Appropriate Cancer Screening Rates			
Breast Cancer Screening	19,092	42,919	44%
Cervical Cancer Screening	39,220	93,499	42%
Colorectal Cancer Screening	55,693	256,997	22%
Color Cottal Gallicer Sol Certifig	33,033	230,331	/0

REDUCING LOW VALUE CARE	Numerator	Denominator	Rate
Utilization and Cost of Avoidable Emergency Room Visits			
Potentially Avoidable ED Visits - As a Percentage of Total ED Visits	45,846	309,597	15%
Potentially Avoidable ED Visits - Per 1,000 Member Months	45,846	11,225	4.1
Potentially Avoidable ED Visits - Per Member Per Year	45,846	935,409	0.05
Low Value Services as Captured by the MedInsight Health Waste Calculator			
Don't obtain baseline laboratory studies in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery – specifically complete blood count, basic or comprehensive metabolic panel, coagulation studies when blood loss (or fluid shifts) is/are expected to be minimal	71,436	90,012	79%
Don't obtain EKG, chest X-rays or pulmonary function test in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery	4,095	81,016	5%
Don't perform population based screening for 25-OH-Vitamin D deficiency	14,426	68,839	21%
Don't perform PSA-based screening for prostate cancer in all men regardless of age	40,574	56,929	71%
Don't do imaging for low back pain within the first six weeks, unless red flags are present	7,789	9,347	83%
Inappropriate Preventable Hospital Stays			
Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate (per 100,000 population)	14,480	657,728	2,202
INCREASING HIGH VALUE CARE	Numerator	Denominator	Rate
Virginia Children and Adolescents who are Current with Appropriate Vaccination Schedules			
Childhood Immunization Status: DTaP	3,249	6,607	49%
Childhood Immunization Status: Influenza	2,838	6,607	43%
Childhood Immunization Status: Hepatitis A	4,937	6,607	75%
Childhood Immunization Status: Hepatitis B	1,117	6,607	17%
Childhood Immunization Status: HiB	4,733	6,607	72%
Childhood Immunization Status: IPV	4,030	6,607	61%
Childhood Immunization Status: MMR	5,291	6,607	80%
Childhood Immunization Status: Pneumococcal Conjugate	3,453	6,607	52%
Childhood Immunization Status: Rotavirus	3,239	6,607	49%
Childhood Immunization Status: VZV	5,296	6,607	80%
Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents	438	3,542	12%
Immunizations for Adolescents: HPV Vaccine	805	7,354	11%
Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine	3,937	7,355	54%
Immunizations for Adolescents: Tdap Vaccine	5,296	7,354	72%
Screening and Treatment of Virginia's Diabetic and Pre-Diabetic Population			
Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)	see CP	R Scorecard 2.0	
Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening	Соі	ming in 2019	
Clinically Appropriate Cancer Screening Rates			
Breast Cancer Screening	24,562	44,108	56%
Cervical Cancer Screening	48,989	97,791	50%
Colorectal Cancer Screening	58,810	219,294	27%

REDUCING LOW VALUE CARE	Numerator	Denominator	Rate
Utilization and Cost of Avoidable Emergency Room Visits			
Potentially Avoidable ED Visits - As a Percentage of Total ED Visits	53,564	376,117	14%
Potentially Avoidable ED Visits - Per 1,000 Member Months	53,564	13,465	4.0
Potentially Avoidable ED Visits - Per Member Per Year	53,564	1,122,074	0.05
Low Value Services as Captured by the MedInsight Health Waste Calculator	33,30 .	1,122,07	0.03
Don't obtain baseline laboratory studies in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery – specifically complete blood count, basic or comprehensive metabolic panel, coagulation studies when blood loss (or fluid shifts) is/are expected to be minimal	101,576	123,010	83%
Don't obtain EKG, chest X-rays or pulmonary function test in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery	5,096	96,634	5%
Don't perform population based screening for 25-OH-Vitamin D deficiency	17,334	113,381	15%
Don't perform PSA-based screening for prostate cancer in all men regardless of age	42,760	58,064	74%
Don't do imaging for low back pain within the first six weeks, unless red flags are present	7,126	9,364	76%
Inappropriate Preventable Hospital Stays	,	•	
Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate (per 100,000 population)	17,510	752,425	2,327
INCREASING HIGH VALUE CARE	Numerator	Denominator	Rate
Virginia Children and Adolescents who are Current with Appropriate Vaccination Schedules			
Childhood Immunization Status: DTaP	4,513	7,729	58%
Childhood Immunization Status: Influenza	3,501	7,729	45%
Childhood Immunization Status: Hepatitis A	6,067	7,729	78%
Childhood Immunization Status: Hepatitis B	908	7,729	12%
Childhood Immunization Status: HiB	5,888	7,729	76%
Childhood Immunization Status: IPV	5,447	7,729	70%
Childhood Immunization Status: MMR	6,410	7,729	83%
Childhood Immunization Status: Pneumococcal Conjugate	4,573	7,729	59%
Childhood Immunization Status: Rotavirus	4,242	7,729	55%
Childhood Immunization Status: VZV	6,375	7,729	82%
Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents	648	4,209	15%
Immunizations for Adolescents: HPV Vaccine	1,156	8,738	13%
Immunizations for Adolescents: Meningococcal Conjugate or Meningococcal Polysaccharide Vaccine	5,071	8,738	58%
Immunizations for Adolescents: Tdap Vaccine	6,700	8,738	77%
Screening and Treatment of Virginia's Diabetic and Pre-Diabetic Population			
Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)	see CF	R Scorecard 2.0	
Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening	Со	ming in 2019	
Clinically Appropriate Cancer Screening Rates			
Breast Cancer Screening	27,255	46,869	58%
Cervical Cancer Screening	58,247	115,524	50%
Colorectal Cancer Screening	73,349	252,069	29%

## **METHODOLOGY**





Measure	Measure Description	Numerator	Denominator
Breast Cancer Screening	Percentage of women 50-74 years of age who had a mammogram to screen for breast cancer	One or more mammograms during the measurement period or the 15 months prior to the measurement period	Women 52-74 years of age as of the end of the measurement period
Cervical Cancer Screening	Percentage of women 21–64 years of age who were screened for cervical cancer	Women 21–64 years of age who were screened for cervical cancer using either of the following criteria:  - Women age 21–64 who had cervical cytology performed every 3 years  - Women age 30–64 who had cervical cytology/human papillomavirus (HPV) co-testing performed every 5 years	Women 24-64 years of age as of the end of the measurement year
Childhood Immunization Status: DTaP	Percentage of children two years of age who had four diphtheria, tetanus, and acellular pertussis (DTaP) vaccines by their second birthday	At least four DTaP vaccinations, with different dates of service, on or before the child's second birthday	Children who turn 2 years of age during the measurement year
Childhood Immunization Status: Hepatitis A	Percentage of children two years of age who had one hepatitis A (HepA) vaccine by their second birthday	Either of the following on or before the child's second birthday meet criteria:  - At least one hepatitis A vaccination, with a date of service on or before the child's second birthday  - History of hepatitis A illness	Children who turn 2 years of age during the measurement year
Childhood Immunization Status: Hepatitis B	Percentage of children two years of age who had three hepatitis B (HepB) vaccine by their second birthday	Any of the following on or before the child's second birthday meet criteria:  - At least three hepatitis B vaccinations  - One of the three vaccinations can be a newborn hepatitis B vaccination during the eight-day period that begins on the date of birth and ends seven days after the date of birth  - History of hepatitis illness	Children who turn 2 years of age during the measurement year
Childhood Immunization Status: HiB	Percentage of children two years of age who had three HiB vaccine by their second birthday	At least three HiB vaccinations, with different dates of service, on or before the child's second birthday	Children who turn 2 years of age during the measurement year
Childhood Immunization Status: Influenza	Percentage of children two years of age who had two influenza (flu) vaccines by their second birthday	At least two influenza vaccinations, with different dates of service, on or before the child's second birthday	Children who turn 2 years of age during the measurement year
Childhood Immunization Status: IPV	Percentage of children two years of age who had three IPV vaccine by their second birthday	At least three IPV vaccinations, with different dates of service, on or before the child's second birthday	Children who turn 2 years of age during the measurement year

Measure	Measure Description	Numerator	Denominator
Childhood Immunization Status: MMR	Percentage of children two years of age who had one measles, mumps, and rubella (MMR) vaccine by their second birthday	Any of the following on or before the child's second birthday meet criteria:  - At least one MMR vaccination - At least one measles and rubella vaccination and at least one mumps vaccination or history of the illness on the same date of service or on different dates of service - At least one measles vaccination or history of the illness and at least one mumps vaccination or history of the illness and at least one rubella vaccination or history of the illness on the same date of service or on different dates of service	Children who turn 2 years of age during the measurement year
Childhood Immunization Status: Pneumococcal Conjugate	Percentage of children two years of age who had four pneumococcal conjugate (PCV) vaccines by their second birthday	At least four pneumococcal conjugate vaccinations, with different dates of service, on or before the child's second birthday	Children who turn 2 years of age during the measurement year
Childhood Immunization Status: Rotavirus	Percentage of children two years of age who had two or three rotavirus (RV) vaccines by their second birthday	Any of the following on or before the child's second birthday meet criteria:  - At least two doses of the two-dose rotavirus vaccine on different dates of service  - At least three doses of the three-dose rotavirus vaccine on different dates of service  - At least one dose of the two-dose rotavirus vaccine and at least two doses of the three-dose rotavirus vaccine, all on different dates of service	Children who turn 2 years of age during the measurement year
Childhood Immunization Status: VZV	Percentage of children two years of age who had one chicken pox (VZV) vaccine by their second birthday	Either of the following on or before the child's second birthday meet criteria:  - At least one VZV vaccination, with a date of service on or before the child's second birthday  - History of varicella zoster (e.g., chicken pox)	Children who turn 2 years of age during the measurement year
Claims in Virginia's All Payer Claims Database	Percent of Virginia Total Covered Lives with Claims Included in the Virginia All Payer Claims Database	Average monthly enrollement for all insurance types within the Virginia APCD	The total number of individuals covered by any type of insurance as obtained from the Kaiser Family Foundation
Claims in Virginia's All Payer Claims Database	Percent of Virginia Commercially Insured Lives with Claims included in the Virginia All Payer Claims Database	Average monthly enrollment for individuals covered by commercial insurance (both group and individual) within the Virginia APCD	The total number of individuals covered by commercial insurance as obtained from the Kaiser Family Foundation

Measure	Measure Description	Numerator	Denominator
Colorectal Cancer Screening	Percentage of members 50-75 years of age who had appropriate screening for colorectal cancer	One or more screenings for colorectal cancer. Any of the following meet criteria: - Fecal occult blood test (FOBT) during the measurement year. For administrative data, assume the required number of samples were returned, regardless of FOBT type - Flexible sigmoidoscopy during the measurement year or the four years prior to the measurement year - Colonoscopy during the measurement year or the nine years prior to the measurement year or the nine years prior to the measurement year	Members 50-75 years of age as of the end of the measurement year
Don't do imaging for low back pain within the first six weeks, unless red flags are present	Percentage of imaging for low back pain considered to be wasteful	Instances of imaging for low back pain performed within the first six weeks without any red flags present. Red flags include:  - Low back pain without improvement after 6 weeks  - Severe or progressive neurologic deficits  - Back pain in those above 70 years of age  - Cauda equina syndrome  - Cancer or history of cancer  - Fracture  - Ankylosing spondylitis  - Immunosuppression, diabetes mellitus, and intravenous drug use  - Prolonged use of corticosteroids  - Osteoporosis  - Symptomatic spinal stenosis, and/or infection  - When serious underlying conditions are suspected on the basis of history and physical examination	All instances of imaging for low back pain within the first six weeks on members 18 years of age or greater during the measurement year
Don't obtain baseline laboratory studies in patients without significant systemic disease (ASA I or II) undergoing low-risk surgery – specifically complete blood count, basic or comprehensive metabolic panel, coagulation studies when blood loss (or fluid shifts) is/are expected to be minimal	Percentage of baseline laboratory studies performed 30 days or fewer prior to a low-risk surgery considered to be wasteful	Instances of baseline laboratory studies in members without significant systemic disease (ASA I or II) performed 30 days or fewer prior to a low-risk surgery - ASA I indicates a normal healthy patient (e.g., healthy, nonsmoking, no or minimal alcohol use) - ASA II indicates a patient with mild systemic disease (e.g., current smoker, social alcohol drinker, pregnancy, obesity, mild lung disease)	All instances of baseline laboratory studies performed 30 days or fewer prior to a low-risk surgery on members 2 years of age or greater

Measure	Measure Description	Numerator	Denominator
Don't perform population based screening for 25-OH-Vitamin-D deficiency	Percentage of population based screenings for 25-OH-Vitamin-D deficiency considered to be wasteful	Instances of screening for 25-OH-Vitamin-D testing excluding those for members at risk of vitamin-D deficiency. Members at risk of vitamin-D deficiency include:  - Members with chronic conditions that require vitamin-D testing, risk factors for vitamin D deficiency, high risk medication for vitamin-D deficiency, pregnancy, obesity, and recent history of falls and traumatic fractures in members aged 65 years and above	All instances of screening for 25-OH-Vitamin-D testing during the measurement year
Don't perform PSA-based screening for prostate cancer in all men regardless of age	Percentage of PSA-based screenings for prostate cancer in men considered to be wasteful	Instances of PSA-based screening in men without any symptoms. Instances of PSA-based screening in men who have clinical presentations and risk factors for prostate cancer are considered likely wasteful as some of the risk factors (e.g., two or more first-degree relatives with prostate cancer before age 65, black ancestry) cannot be determined through claims data	All instances of PSA-based screening for prostate cancer in men during the measurement year
Human Papillomavirus Virus (HPV) Vaccine for Female Adolescents	Percentage of female adolescents 13 years of age who had three doses of the human papillomavirus (HPV) vaccine by their 13th birthday	At least three HPV vaccinations, with different dates of service, on or between the member's 9th and 13th birthdays	Female adolescents who turn 13 years of age during the measurement year
Immunizations for Adolescents: HPV Vaccine	Percentage of adolescents 13 years of age who had three doses of the human papillovirus (HPV) vaccine by their 13th birthday	Three HPV vaccines, with different dates of service, on or between the member's 9th and 13th birthdays	Adolescents who turn 13 years of age during the measurement year
Immunizations for Adolescents: Meningococcal Conjugate Vaccine	Percentage of adolescents 13 years of age who had one dose of meningococcal conjugate vaccine by their 13th birthday	One meningococcal conjugate vaccine on or between the member's 11th and 13th birthdays	Adolescents who turn 13 years of age during the measurement year
Immunizations for Adolescents: Tdap Vaccine	Percentage of adolescents 13 years of age who had one tetanus, diphtheria toxoids, and acellular pertussis vaccine (Tdap) by their 13th birthday	One tetanus, diphtheria toxoids, and acellular pertussis vaccine (Tdap) on or between the member's 10th and 13th birthdays	Adolescents who turn 13 years of age during the measurement year
Percentage of Commercial In-Network Payments that are Value-Oriented		See CPR Scorecard 2.0	
Percentage of Patients 18-75 Years of Age with Diabetes who had a Nephropathy Screening		Coming in 2019	

Measure	Measure Description	Numerator	Denominator
Percentage of Patients 18-75 Years of Age with Diabetes who had HbA1c Screening During the Measurement Year (HEDIS=1 year)		See CPR Scorecard	
Potentially Avoidable ED Visits - As a Percentage of Total ED Visits	Avoidable ED visits as a percentage of total ED visits	Potentially avoidable ED visits	ED visits overall
Potentially Avoidable ED Visits - Per 1,000 Member Months	Avoidable ED visits per 1,000 member months	Potentially avoidable ED visits	Total medical member months/1,000
Potentially Avoidable ED Visits - Per Member Per Year	Avoidable ED visits per member per year	Potentially avoidable ED visits	Total medical member months/12
Prevention Quality Indicator #90: Prevention Quality Overall Composite Rate (per 100,000 population)	Prevention Quality Indicators (PQI) overall composite per 100,000 population, ages 18 years and older	Discharges, for patients ages 18 years and older, that meet the inclusion and exclusion rules for the numerator in any of the following PQIs: - PQI #1 Diabetes Short-Term Complications Admission Rate - PQI #3 Diabetes Long-Term Complications Admission Rate - PQI #5 Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Admission Rate - PQI #7 Hypertension Admission Rate - PQI #8 Heart Failure Admission Rate - PQI #10 Dehydration Admission Rate - PQI #11 Bacterial Pneumonia Admission Rate - PQI #12 Urinary Tract Infection Admission Rate - PQI #14 Uncontrolled Diabetes Admission Rate - PQI #15 Asthma in Younger Adults Admission Rate - PQI #16 Lower-Extremity Amputation among Patients with Diabetes Rate	Members 18 years of age or older as of the end of the measurement year
Value-Oriented Payments that Place Doctors and Hospitals at Financial Risk for Performance		See CPR Scorecard 2.0	

